Targeting SOX2 in anticancer therapy

References

• Sinclair AH, Berta P, Palmer MS, et al. A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature. 1990;346:240–244.
   PubMed Web of Science ®Google Scholar
• Schepers GE, Teasdale RD, Koopman P. Twenty Pairs of Sox. Dev Cell. 2002;3:167–170.
   PubMed Web of Science ®Google Scholar
• Castillo SD, Sanchez-Cespedes M. The SOX family of genes in cancer development: biological relevance and opportunities for therapy. Expert Opin Ther Targets. 2012;16:903–919.
   PubMed Web of Science ®Google Scholar
• Wegner M. All purpose Sox: the many roles of Sox proteins in gene expression. Int J Biochem Cell Biol. 2010;42:381–390.
   PubMed Web of Science ®Google Scholar
• Collignon J, Sockanathan S, Hacker, et al. A comparison of the properties of Sox-3 with Sry and two related genes, Sox-1 and Sox-2. Development. 1996;122:509–520.
   PubMed Web of Science ®Google Scholar
• Stevanovic M, Zuffardi O, Collignon J, et al. The cDNA sequence and chromosomal location of the human SOX2 gene. Mamm Genome. 1994;5:640–642.
   PubMed Web of Science ®Google Scholar
• Sarkar A, Hochedlinger K. The Sox family of transcription factors: versatile regulators of stem and progenitor cell fate. Cell Stem Cell. 2013;12:15–30.
   PubMed Web of Science ®Google Scholar
• Adameyko I, Lallemend F, Furlan A, et al. Sox2 and Mitf cross-regulatory interactions consolidate progenitor and melanocyte lineages in the cranial neural crest. Development. 2012;139:397–410.
   PubMed Web of Science ®Google Scholar
• Boyer LA, Lee TI, Cole MF, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005 Sep 23;122(6):947–956.
   PubMed Web of Science ®Google Scholar
• Wang J, Rao S, Chu J, et al. A protein interaction network for pluripotency of embryonic stem cells. Nature. 2006 Nov 16;444(7117):364–368.
   PubMed Web of Science ®Google Scholar
• Kim J, Chu J, Shen X, et al. An extended transcriptional network for pluripotency of embryonic stem cells. Cell. 2008 Mar 21;132(6):1049–1061.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–676.
   PubMed Web of Science ®Google Scholar
• Eminli S, Utikal J, Arnold K, et al. Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. Stem Cells. 2008;26:2467–2474.
   PubMed Web of Science ®Google Scholar
• Utikal J, Maherali N, Kulalert W, et al. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci. 2009;122:3502–3510.
   PubMed Web of Science ®Google Scholar
• Williamson KA, Hever AM, Rainger J, et al. Mutations in SOX2 cause anophthalmia-esophageal-genital (AEG) syndrome. Hum Mol Genet. 2006;15:1413–1422.
   PubMed Web of Science ®Google Scholar
• Weina K, Utikal J. SOX2 and cancer: current research and its implications in the clinic. Clin Transl Med. 2014;3:19.
   Google Scholar
• Wuebben EL, Rizzino A. The dark side of SOX2 : cancer - a comprehensive overview. Oncotarget. 2017;8(27):44917-44943.
   Google Scholar
• Gen Y, Yasui K, Zen Y, et al. SOX2 identified as a target gene for the amplification at 3q26 that is frequently detected in esophageal squamous cell carcinoma. Cancer Genet Cytogenet. 2010;202:82–93.
   PubMedGoogle Scholar
• Lin SC, Chou YT, Jiang SS, et al. Epigenetic switch between SOX2 and SOX9 regulates cancer cell plasticity. Cancer Res. 2016;76:7036–7048.
   PubMed Web of Science ®Google Scholar
• Chou YT, Lee CC, Hsiao SH, et al. The emerging role of SOX2 in cell proliferation and survival and its crosstalk with oncogenic signaling in lung cancer. Stem Cells. 2013;31:2607–2619.
   PubMed Web of Science ®Google Scholar
• Herreros-Villanueva M, Zhang J-S, Koenig A, et al. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Oncogenesis. 2013;2:e61.
   PubMed Web of Science ®Google Scholar
• Chen S, Li X, Lu D, et al. SOX2 regulates apoptosis through MAP4K4-Survivin signaling pathway in human lung cancer cells. Carcinogenesis. 2014;35:613–623.
   PubMed Web of Science ®Google Scholar
• Jia X, Li X, Xu Y, et al. SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol. 2011;3:230–238.
   PubMed Web of Science ®Google Scholar
• Ren C, Ren T, Yang K, et al. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing’s sarcoma through the PI3K/Akt pathway. J Exp Clin Cancer Res. 2016;35:1–14.
   PubMed Web of Science ®Google Scholar
• Maurizi G, Verma N, Gadi A, et al. Sox2 is required for tumor development and cancer cell proliferation in osteosarcoma. Oncogene. 2018;37(33):4626-4632.
   Web of Science ®Google Scholar
• Santini R, Pietrobono S, Pandolfi S, et al. SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells. Oncogene. 2014;33(38):4697-708.
   Web of Science ®Google Scholar
• Han X, Fang X, Lou X, et al. Silencing SOX2 induced mesenchymal-epithelial transition and its expression predicts liver and lymph node metastasis of CRC patients. PLoS One. 2012;7(8):e41335.
   Google Scholar
• Sun C, Sun L, Li Y, et al. Sox2 expression predicts poor survival of hepatocellular carcinoma patients and it promotes liver cancer cell invasion by activating Slug. Med Oncol. 2013;30(2):503.
   Web of Science ®Google Scholar
• Drakulic D, Vicentic JM, Schwirtlich M, et al. The overexpression of SOX2 affects the migration of human teratocarcinoma cell line NT2/D1. An Acad Bras Cienc. 2015;87:389–405.
   PubMed Web of Science ®Google Scholar
• Kar S, Sengupta D, Deb M, et al. SOX2 function and Hedgehog signaling pathway are co-conspirators in promoting androgen independent prostate cancer. Biochim Biophys Acta Mol Basis Dis. 2017;1863:253–265.
   Web of Science ®Google Scholar
• Liu K, Xie F, Gao A, et al. SOX2 regulates multiple malignant processes of breast cancer development through the SOX2/miR-181a-5p, miR-30e-5p/TUSC3 axis. Mol Cancer. 2017;16:1–14.
   PubMed Web of Science ®Google Scholar
• Girouard SD, Laga AC, Mihm MC, et al. SOX2 contributes to melanoma cell invasion. Lab Investig. 2012;92:362–370.
   PubMed Web of Science ®Google Scholar
• Weina K, Wu H, Knappe N, et al. TGF- β induces SOX2 expression in a time-dependent manner in human melanoma cells. Pigment Cell Melanoma Res. 2016;29(4):453-8.
   PubMed Web of Science ®Google Scholar
• Ikushima H, Todo T, Ino Y, et al. Autocrine TGF-β signaling maintains tumorigenicity of glioma-initiating cells through sry-related HMG-box factors. Cell Stem Cell. 2009;5:504–514.
   PubMed Web of Science ®Google Scholar
• Alonso MM, Diez-Valle R, Manterola L, et al. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One. 2011;6(11):e26740.
   Web of Science ®Google Scholar
• Wang X, Ji X, Chen J, et al. SOX2 enhances the migration and invasion of ovarian cancer cells via Src kinase. PLoS One. 2014;9(6):e99594.
   Web of Science ®Google Scholar
• Lou X, Han X, Jin C, et al. SOX2 targets fibronectin 1 to promote cell migration and invasion in ovarian cancer: new molecular leads for therapeutic intervention. Omi J Integr Biol. 2013;17:510–518.
   PubMed Web of Science ®Google Scholar
• Yang N, Wang Y, Hui L, et al. Silencing SOX2 expression by rna interference inhibits proliferation, invasion and metastasis, and induces apoptosis through MAP4K4/JNK signaling pathway in human laryngeal cancer TU212 cells. J Histochem Cytochem. 2015;63:721–733.
   PubMed Web of Science ®Google Scholar
• Yang N, Hui L, Wang Y, et al. SOX2 promotes the migration and invasion of laryngeal cancer cells by induction of MMP-2 via the PI3K/Akt/mTOR pathway. Oncol Rep. 2014;31:2651–2659.
   PubMed Web of Science ®Google Scholar
• Otsubo T, Akiyama Y, Yanagihara K, et al. SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer. 2008;98:824–831.
   PubMed Web of Science ®Google Scholar
• Wang S, Tie J, Wang R, et al. SOX2, a predictor of survival in gastric cancer, inhibits cell proliferation and metastasis by regulating PTEN. Cancer Lett. 2015;358:210–219.
   PubMed Web of Science ®Google Scholar
• Hütz K, Mejías-Luque R, Farsakova K, et al. The stem cell factor SOX2 regulates the tumorigenic potential in human gastric cancer cells. Carcinogenesis. 2014;35:942–950.
   PubMed Web of Science ®Google Scholar
• Schaefer SM, Segalada C, Cheng PF, et al. Sox2 is dispensable for primary melanoma and metastasis formation. Oncogene. 2017;36(31):4516-4524.
   Web of Science ®Google Scholar
• Cesarini V, Guida E, Todara F, et al. Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo. Oncogene. 2017;36(31):4508-4515.
   Web of Science ®Google Scholar
• Zhang J, Chang DY, Mercado-Uribe I, et al. Sex-determining region Y-box 2 expression predicts poor prognosis in human ovarian carcinoma. Hum Pathol. 2012;43:1405–1412.
   PubMed Web of Science ®Google Scholar
• Wilbertz T, Wagner P, Petersen K, et al. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol. 2011;24:944–953.
   PubMed Web of Science ®Google Scholar
• Zhu P, Fan Z. Cancer stem cells and tumorigenesis. Biophys Rep. 2018;4(4):178–188.
   PubMedGoogle Scholar
• Jin X, Jin X, Kim H. Cancer stem cells and differentiation therapy. Tumor Biol. 2017;39:1–11.
   Google Scholar
• Dogan I, Kawabata S, Bergbower E, et al. SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines. Lung Cancer. 2014;85:1–6.
   PubMed Web of Science ®Google Scholar
• Sachindra, Larribère L, Novak D, et al. New role of ID3 in melanoma adaptive drug-resistance. Oncotarget.. 2017;8:110166–110175.
   PubMedGoogle Scholar
• Bernhardt M, Novak D, Assenov Y, et al. Melanoma-derived iPCCs show differential tumorigenicity and therapy response. Stem Cell Reports. 2017; 8(5):1379-1391.
   Web of Science ®Google Scholar
• Piva M, Domenici G, Iriondo O, et al. Sox 2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol Med. 2014;6:66–79.
   PubMed Web of Science ®Google Scholar
• Lundberg IV, Edin S, Eklöf V, et al. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer. BMC Cancer. 2016;16:471.
   PubMed Web of Science ®Google Scholar
• Bareiss PM, Paczulla A, Wang H, et al. SOX2 expression associates with stem cell state in human ovarian carcinoma. Cancer Res. 2013;73:5544–5555.
   PubMed Web of Science ®Google Scholar
• Justilien V, Walsh MP, Ali SA, et al. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate hedgehog signaling in lung squamous cell carcinoma. Cancer Cell. 2014;25::139–151.
   PubMed Web of Science ®Google Scholar
• Mukherjee P, Gupta A, Chattopadhyay D, et al. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells. Sci Rep. 2017;7:1–16.
   PubMed Web of Science ®Google Scholar
• Yang J, Liao D, Chen C, et al. Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2. Stem Cells. 2013;31:248–258.
   PubMed Web of Science ®Google Scholar
• Song WS, Yang YP, Huang CS, et al. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells. J Chinese Med Assoc. 2016;79:538–545.
   PubMed Web of Science ®Google Scholar
• Vanner R, Remke M, Gallo M, et al. Quiescent Sox2+ cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma. Cancer Cell. 2014;26:33–47.
   PubMed Web of Science ®Google Scholar
• Jeon HM, Sohn YW, Oh SY, et al. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res. 2011;71:3410–3421.
   PubMed Web of Science ®Google Scholar
• Tian T. Sox2 enhances the tumorigenicity and chemoresistance of cancer stem-like cells derived from gastric cancer. J Biomed Res. 2012;26:336–345.
   PubMedGoogle Scholar
• Lee SH, Oh SY, Do SI, et al. SOX2 regulates self-renewal and tumorigenicity of stem-like cells of head and neck squamous cell carcinoma. Br J Cancer. 2014;111:2122–2130.
   PubMed Web of Science ®Google Scholar
• Li D, Zhao LN, Zheng XL, et al. Sox2 is involved in paclitaxel resistance of the prostate cancer cell line PC-3 via the PI3K/Akt pathway. Mol Med Rep. 2014;10:3169–3176.
   PubMed Web of Science ®Google Scholar
• Li Y, Chen K, Li L, et al. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway. Tumor Biol. 2015;36:9823–9828.
   PubMedGoogle Scholar
• Garros-Regulez L, Aldaz P, Arrizabalaga O, et al. mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance. Expert Opin Ther Targets. 2016;20:393–405.
   PubMed Web of Science ®Google Scholar
• Xie LX, Sun FF, He BF, et al. Rapamycin inhibited the function of lung CSCs via SOX2. Tumor Biol. 2016;37:4929–4937.
   PubMedGoogle Scholar
• Saigusa S, Tanaka K, Toiyama Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol. 2009;16:3488–3498.
   PubMed Web of Science ®Google Scholar
• Shen L, Huang X, Xie X, et al. High expression of SOX2 and OCT4 indicates radiation resistance and an independent negative prognosis in cervical squamous cell carcinoma. J Histochem Cytochem. 2014;62:499–509.
   PubMed Web of Science ®Google Scholar
• Mu P, Zhang Z, Benelli M, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer. Sci (80-.). 2017;355:84–88.
   PubMed Web of Science ®Google Scholar
• Bora-Singhal N, Perumal D, Nguyen J, et al. Gli1-mediated regulation of Sox2 facilitates self-renewal of stem-like cells and confers resistance to EGFR inhibitors in non-small cell lung cancer. Neoplasia. 2015;17:538–551.
   PubMed Web of Science ®Google Scholar
• Hüser L, Sachindra, Granados K, et al. SOX2-mediated upregulation of CD24 promotes adaptive resistaance towards targeted therapy in melanoma. Int J Cancer. 2018. doi: 10.1002/ijc.31609. [Epub ahead of print]
   PubMedGoogle Scholar
• Gangemi RMR, Griffero F, Marubbi D, et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells. 2009;27:40–48.
   PubMed Web of Science ®Google Scholar
• Dong H, Hao X, Cui B, et al. MiR-429 suppresses glioblastoma multiforme by targeting SOX2. Cell Biochem Funct. 2017;35:260–268.
   PubMed Web of Science ®Google Scholar
• Zhao C, Li Y, Zhang M, et al. miR-126 inhibits cell proliferation and induces cell apoptosis of hepatocellular carcinoma cells partially by targeting Sox2. Hum Cell. 2015;28:91–99.
   PubMed Web of Science ®Google Scholar
• Nawata J, Kuramitsu Y, Wang Y, et al. Active hexose-correlated compound down-regulates sex-determining region Y-box 2 of pancreatic cancer cells. Anticancer Res. 2014;34:4807–4811.
   PubMed Web of Science ®Google Scholar
• Yokota E, Yamatsuji T, Takaoka M, et al. Targeted silencing of SOX2 by an artificial transcription factor showed antitumor effect in lung and esophageal squamous cell carcinoma. Oncotarget. 2017;8:103063–103076.
   PubMedGoogle Scholar
• Stolzenburg S, Rots MG, Beltran AS, et al. Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res. 2012;40:6725–6740.
   PubMed Web of Science ®Google Scholar
• Favaro R, Appolloni I, Pellegatta S, et al. Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma. Cancer Res. 2014;74:1833–1844.
   PubMed Web of Science ®Google Scholar
• Schmitz M, Temme A, Senner V, et al. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer. 2007;96:1293–1301.
   PubMed Web of Science ®Google Scholar
• Dhodapkar KM, Gettinger SN, Das R, et al. SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer. Oncoimmunology. 2013;2(7):e25205.
   Web of Science ®Google Scholar
• Ji J, Yu Y, Li ZL, et al. XIAP limits autophagic degradation of Sox2 and is a therapeutic target in nasopharyngeal carcinoma stem cells. Theranostics. 2018;8:1494–1510.
   PubMed Web of Science ®Google Scholar
• Zhang X, Lu F, Wang J, et al. Pluripotent stem cell protein Sox2 confers sensitivity to LSD1 inhibition in cancer cells. Cell Rep. 2013;5:445–457.
   PubMed Web of Science ®Google Scholar
• Wang J, Lu F, Ren Q, et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res. 2011;71:7238–7249.
   PubMed Web of Science ®Google Scholar
• Singh S, Trevino J, Bora-Singhal N, et al. EGFR_Src_Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer. 2012;11:73.
   Web of Science ®Google Scholar
• Pietrobono S, Morandi A, Gagliardi S, et al. Down-regulation of SOX2 underlies the inhibitory effects of the triphenylmethane gentian violet on melanoma cell self-renewal and survival. J Invest Dermatol. 2016;136:2059–2069.
   PubMed Web of Science ®Google Scholar
• Kim BR, Coyaud E, Laurent EMN, et al. Identification of the SOX2 interactome by BioID reveals EP300 as a mediator of SOX2-dependent squamous differentiation and lung squamous cell carcinoma growth. Mol Cell Proteomics. 2017;16:1864–1888.
   PubMed Web of Science ®Google Scholar